A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy

Inclusion Criteria:

1. Age 18-80;

2. Diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior toor during screening;

3. Screening 24-hour urinary protein >= 5 g after best supportive care for >= 3 monthsprior to screening or screening Screening 24-hour urinary protein > 3.5 g after bestsupportive care for >= 6 months prior to screening, or Screening 24-hour urinaryprotein > 3.5 g with at least one high-risk factor defined by the protocol;

4. Estimated glomerular filtration rate (eGFR ) by Chronic Kidney Disease EpidemiologyCollaboration (CKD-EPI) formula ≥40 mL/min/1.73 m^2;

5. If taking ACEI(Angiotensin converting enzyme inhibitors), ARB(Angiotensin receptorblocker), a stable dose within 4 weeks before screening is required;

6. Sufficient organ function;

7. Able and willing to provide written informed consent and to comply with the studyprotocol.

Exclusion Criteria:

1. Participants with a secondary cause of MN;

2. Cyclosporine resistance;

3. Received treatment drugs for membranous nephropathy;

4. Concomitant with other serious diseases；

5. Received live vaccination, major surgery (excluding diagnostic procedures), andparticipated in other clinical trials within 28 days prior to receiving the firststudy drug;

6. Patients who are positive for hepatitis B surface antigen (HBsAg) and/or hepatitis Bcore antibody (HBcAb), with HBV DNA levels above the normal range (HBsAg and/orHBcAb-positive patients require regular HBV DNA testing); patients positive forhepatitis C virus (HCV) antibodies; or patients with a positive humanimmunodeficiency virus (HIV) serology.

7. Participants with CD4+ T lymphocyte count < 200 cells/μL;

8. Those who have a clear history of tuberculosis or have received anti- tuberculosistreatment;

9. Participants with known history of severe allergic reactions to humanized monoclonalantibodies, MIL62, or Cyclosporine

10. Breastfeeding or pregnant women;

11. Childbearing potential and unwillingness or impossibility to comply with ascientifically acceptable birth-control method

12. Other conditions unsuitable for participation in this study determined by theInvestigator.